Getting older – but healthy, please! How Senolytic Agents Could Revolutionise Ageing Research
Each of us wants to grow old – but no one wants to be old. Age is often associated with life experience, wisdom, and a sense of calm, but also with physical limitations, pain, and illness.
This is the question that Johannes Grillari tackles, Director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma), the research centre in cooperation with the AUVA, and one of the world’s leading scientists in the field of cellular ageing. Together with his team, he is exploring how ageing processes can be better understood – and perhaps even controlled. At the heart of this research is a phenomenon linked to nearly all age-related diseases: cellular senescence.
When cells retire
Senescent cells are cells that have stopped dividing – essentially entering a kind of cellular retirement. But that doesn’t mean they quietly disappear. On the contrary, they remain metabolically active and send out constant signals that can disrupt the function of surrounding cells. This behaviour, known as the senescence-associated secretory phenotype (SASP), results in the release of inflammatory messengers, pro-thrombotic factors, and tissue-degrading enzymes.
As we age, senescent cells build up in the body, triggered by injuries, stress (e.g. UV radiation, DNA damage, oxidative stress), or simply time. In younger individuals, the immune system usually clears these cells efficiently. In older bodies, this process becomes less reliable. The result: senescent cells linger in tissues, inhibit healthy cell function, weaken the immune system, and contribute to the development or progression of many age-related diseases – from cardiovascular disorders and neurodegenerative conditions like Alzheimer’s and Parkinson’s, to musculoskeletal disorders, pulmonary fibrosis, and chronic kidney disease.
Senescent cells also impair regeneration. In the context of injury, they reduce the regenerative potential of surrounding tissues; one reason why wounds or bone fractures heal more slowly in old age.
Senolytics: A new hope in regenerative and ageing medicine
This is where senolytics come in – drugs that can selectively identify and eliminate senescent cells. In mice, removing these “troublemakers” has been shown to improve tissue function, reduce inflammation, and boost healing. Treated animals not only recovered faster but also appeared more vital and active, sometimes even visibly younger.
While these findings are promising, they haven’t yet translated into approved treatments for humans. However, clinical trials are underway, especially in the US, testing senolytics in conditions like pulmonary fibrosis, liver disease, and early-stage Alzheimer’s. One promising combination includes Dasatinib, a cancer drug, and Quercetin, a natural compound found in apples and onions. Early results suggest improvements in physical function.
Researchers at LBI Trauma are also investigating a new senolytic agent identified through their own work, and they’re enthusiastic about its potential. To move this compound toward clinical application, a spin-off company has been founded, stemming from research at the University of Natural Resources and Life Sciences (BOKU), the Medical University of Vienna, and LBI Trauma.
“Our hope,” Grillari says, “is to relieve the body of harmful cells, without removing the ones that still serve a purpose.”
That’s important, because not all senescent cells are bad. Temporary senescence plays key roles in embryonic development and the early stages of wound healing. In these cases, the SASP signals actually help remodel tissues. You could say a bit of cellular “complaining” can be productive: it draws attention to problems and initiates change. But if the complaints become constant and purposeless, they start to do more harm than good. The same applies in the body.
MICSE: A common language for senescence research
To help researchers around the world investigate senescence in a consistent and comparable way, Grillari and colleague Mikolaj Ogrodnik developed the MICSE guidelines — Minimal Information on Cellular Senescence Experimentation in vivo. For the first time, these guidelines offer a standardised framework for identifying and studying senescent cells in living organisms. They define which markers are reliable, which combinations of methods should be used, and how different tissue types – from biopsies to fluid samples – can be analysed.
The result is not only a practical guide, but also a milestone in international scientific collaboration. Researchers from around the globe joined forces to lay the groundwork for more unified ageing research. The MICSE guidelines were published in Cell in 2024.
Not Immortality, but Healthy Ageing
“Our goal isn’t to defeat death,” Grillari emphasises. “It’s to make the time we have as healthy and fulfilling as possible.” Instead of chasing immortality, his research focuses on extending healthspan, not just lifespan. If used wisely and carefully, senolytics could one day help reduce the burden of chronic diseases. Because one thing is certain: ageing is inevitable.
But how we age might still be within our control.
